TY - JOUR
T1 - Mortality and Lithium-Protective Effects after First-Episode Mania Diagnosis in Bipolar Disorder
T2 - A Nationwide Retrospective Cohort Study in Taiwan
AU - Carvalho, Andre F.
AU - Hsu, Chih Wei
AU - Vieta, Eduard
AU - Solmi, Marco
AU - Marx, Wolfgang
AU - Berk, Michael
AU - Liang, Chih Sung
AU - Tseng, Ping Tao
AU - Wang, Liang Jen
N1 - © 2024 The Author(s). Published by S. Karger AG, Basel.
PY - 2024
Y1 - 2024
N2 - Introduction: This study aimed to estimate all-cause mortality in patients after a first-episode mania (FEM) and examine whether six guideline-recommended medications can reduce mortality. Methods: The cohort included population-based FEM samples and matched controls from Taiwan, spanning 2007 to 2018. The primary outcomes assessed were all-cause/suicide-related mortality, while the secondary outcome focused on mortality associated with pharmacological treatments. We compared mortality in post-FEM patients and age-/sex-matched controls without any diagnosed bipolar disorders and patients with and without psychopharmacological treatment using Cox regression analysis, respectively. Statistics were presented with time-to-event adjusted hazard ratios (AHRs) and 95% confidence intervals (CIs). Results: The study included 54,092 post-FEM patients and 270,460 controls, totaling 2,467,417 person-years of follow-up. Post-FEM patients had higher risks of all-cause mortality (AHR 2.38, 95% CI: 2.31-2.45) and suicide death (10.80, 5.88-19.84) than controls. Lithium (0.62, 0.55-0.70), divalproex (0.89, 0.83-0.95), and aripiprazole (0.81, 0.66-1.00) were associated with reduced all-cause mortality compared to non-users. There were no significant all-cause mortality differences for quetiapine (0.95, 0.89-1.01), risperidone (0.92, 0.82-1.02), and paliperidone (1.24, 0.88-1.76) users. When accounting for drug action onset times in sensitivity analyses, only lithium significantly reduced all-cause mortality (AHR range 0.65-0.72). There were 35 and 16 suicide deaths in post-FEM patients and controls, respectively. No drug had a significant effect on suicide deaths (lithium: 6; divalproex: 7; aripiprazole: 0; quetiapine: 10; risperidone: 4; paliperidone: 1). Conclusion: Post-FEM patients had a higher risk of all-cause/suicide-related mortality, and lithium treatment might reduce all-cause mortality.
AB - Introduction: This study aimed to estimate all-cause mortality in patients after a first-episode mania (FEM) and examine whether six guideline-recommended medications can reduce mortality. Methods: The cohort included population-based FEM samples and matched controls from Taiwan, spanning 2007 to 2018. The primary outcomes assessed were all-cause/suicide-related mortality, while the secondary outcome focused on mortality associated with pharmacological treatments. We compared mortality in post-FEM patients and age-/sex-matched controls without any diagnosed bipolar disorders and patients with and without psychopharmacological treatment using Cox regression analysis, respectively. Statistics were presented with time-to-event adjusted hazard ratios (AHRs) and 95% confidence intervals (CIs). Results: The study included 54,092 post-FEM patients and 270,460 controls, totaling 2,467,417 person-years of follow-up. Post-FEM patients had higher risks of all-cause mortality (AHR 2.38, 95% CI: 2.31-2.45) and suicide death (10.80, 5.88-19.84) than controls. Lithium (0.62, 0.55-0.70), divalproex (0.89, 0.83-0.95), and aripiprazole (0.81, 0.66-1.00) were associated with reduced all-cause mortality compared to non-users. There were no significant all-cause mortality differences for quetiapine (0.95, 0.89-1.01), risperidone (0.92, 0.82-1.02), and paliperidone (1.24, 0.88-1.76) users. When accounting for drug action onset times in sensitivity analyses, only lithium significantly reduced all-cause mortality (AHR range 0.65-0.72). There were 35 and 16 suicide deaths in post-FEM patients and controls, respectively. No drug had a significant effect on suicide deaths (lithium: 6; divalproex: 7; aripiprazole: 0; quetiapine: 10; risperidone: 4; paliperidone: 1). Conclusion: Post-FEM patients had a higher risk of all-cause/suicide-related mortality, and lithium treatment might reduce all-cause mortality.
KW - Bipolar disorder
KW - Depression
KW - Lithium
KW - Mania
KW - Mortality
KW - Lithium/therapeutic use
KW - Humans
KW - Paliperidone Palmitate/therapeutic use
KW - Bipolar Disorder/drug therapy
KW - Aripiprazole
KW - Antipsychotic Agents/adverse effects
KW - Taiwan/epidemiology
KW - Mania/chemically induced
KW - Valproic Acid/adverse effects
KW - Risperidone/adverse effects
KW - Quetiapine Fumarate/therapeutic use
KW - Retrospective Studies
UR - https://www.scopus.com/pages/publications/85182553342
U2 - 10.1159/000535777
DO - 10.1159/000535777
M3 - 文章
C2 - 38194936
AN - SCOPUS:85182553342
SN - 0033-3190
VL - 93
SP - 36
EP - 45
JO - Psychotherapy and Psychosomatics
JF - Psychotherapy and Psychosomatics
IS - 1
ER -